Methods of modifying eukaryotic cells

• US 6,596,541 B2
• Filed: 02/16/2001
• Issued: 07/22/2003
• Est. Priority Date: 10/31/2000
• Status: Expired due to Term

• Current Assignee: Regeneron Pharmaceuticals Incorporated
• Original Assignee: Regeneron Pharmaceuticals Incorporated
• Inventors: Yancopoulos, George D., Murphy, Andrew J.
• Primary Examiner(s): Crouch, Deborah
• Assistant Examiner(s): Ton, Thaian N.
• Application Number:
  US09/784,859
• Publication Number:
  US 20020106629A1
• Time in Patent Office: 886 Days
• Field of Search: 435/172.3, 435/320.1, 435/328, 435/372.3, 435/69.1, 435/70.21, 435/325, 435/326, 435/463, 435/440, 435/455, 536/23.1, 536/23.51
• US Class Current: 435/463
• CPC Class Codes: A01K 2207/15 Humanized animals
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/01 Animal expressing industrially exogenous proteins
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A01K 67/0278 Knock-in vertebrates, e.g. humanised vertebrates
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/462 Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
• CPC Class Codes: C07K 2317/10 characterized by their source of isolation or production
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/51 Complete heavy chain or Fd fragment, i.e. VH + CH1
• CPC Class Codes: C07K 2317/515 Complete light chain, i.e. VL + CL
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C12N 15/67 General methods for enhancing the expression
• CPC Class Codes: C12N 15/85 for animal cells
• CPC Class Codes: C12N 15/8509 for producing genetically modified animals, e.g. transgenic
• CPC Class Codes: C12N 15/902 using homologous recombination
• CPC Class Codes: C12N 15/907 in mammalian cells
• CPC Class Codes: C12N 2800/204 : of bacterial origin, e.g. BAC
• CPC Class Codes: C12P 21/00 : Preparation of peptides or proteins single cell protein C12N1/00

Abstract

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

Claims

1. A method of replacing, in whole or in part, in an isolated non-human eukaryotic cell, an endogenous immunoglobulin variable region gene locus with an homologous or orthologous human immunoglobulin variable gene locus comprising:

a) obtaining a large cloned genomic fragment greater than 20 kb containing, in whole or in part, the homologous or orthologous human immunoglobulin variable gene locus;

b) using bacterial homologous recombination to genetically modify the cloned genomic fragment of (a) to create a large targeting vector for use in the eukaryotic cells (LTVEC), the LTVEC having homology arms totaling greater than 20 kb;

c) introducing the LTVEC of (b) into the isolated eukaryotic cells to replace by homologous recombination, in whole or in part, the endogenous immunoglobulin variable gene locus; and

d) using a quantitative assay to detect modification of allele (MOA) in the eukaryotic cells of (c) to identify those eukaryotic cells in which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human immunoglobulin variable gene locus.

2. The method of claim 1 further comprising:

e) obtaining a large cloned genomic fragment greater than 20 kb containing a part of the homologous or orthologous human immunoglobulin variable gene locus that differs from the fragment of (a);

f) using bacterial Homologous recombination to genetically modify the cloned genomic fragment of (e) to create a second LTVEC, the second LTVEC having homology arms totaling greater than 20 kb;

g) introducing the second LTVEC of (f) into the eukaryotic cells identified in step (d) to replace by homologous recombination, in whole or in part, the endogenous immunoglobulin variable gene locus; and

h) using a quantitative assay to detect modification of allele (MOA) in the eukaryotic cells of (g) to identify those eukaryotic cells ii which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human immunoglobulin variable region gene locus.

3. The method of claim 2 wherein steps (e) through (h) are repeated until the endogenous immunoglobulin variable region gene locus is replaced in whole with an homologous or orthologous human immunoglobulin variable region gene locus.

4. The method of claim 1 wherein the immunoglobulin variable gene locus is a locus selected from the group consisting of:

a) a variable gene locus of the kappa light chain;

b) a variable gene locus of the lambda light chain; and

c) a variable gene locus of the heavy chain.

5. The method of claim 4 wherein the quantitative assay comprises quantitative PCR, FISH, comparative genomic hybridization, isothermic DNA amplification, or quantitative hybridization to an immobilized probe.

6. The method of claim 5 wherein the quantitative PCR comprises TaqMan®

technology or quantitative PCR using molecular beacons.

11. An isolated genetically modified immunoglobulin variable region gene locus produced by the method of claim 3 or 9.

12. A genetically modified eukaryotic cell comprising a genetically modified immunoglobulin variable region gene locus produced by the method of claim 3 or 9.

13. An isolated mouse embryonic stem cell containing a genetically modified immunoglobulin variable region gene locus produced by the method of claim 3 or 9.

14. The embryonic stem cell of claim 13 wherein the mouse heavy chain variable region locus is replaced with a human heavy chain variable gene locus.

15. The embryonic stem cell of claim 13 wherein the mouse kappa light chain variable region locus is replaced with a human kappa light chain variable region locus.

16. The embryonic stem cell of claim 13 wherein the mouse lambda light chain variable region locus is replaced with a human lambda light chain variable region locus.

17. The embryonic stem cell of claim 13 wherein the heavy and light chain variable region gene loci are replaced with their human homologs or orthologs.

7. A method of replacing, in whole or in part, in an isolated mouse embryonic stem cell, an endogenous immunoglobulin variable region gene locus with the homologous or orthologous human immunoglobulin variable gene locus comprising:

a) obtaining a large cloned genomic fragment greater than 20 kb containing, in whole or in part, the homologous or orthologous human immunoglobulin variable gene locus;

b) using bacterial homologous recombination to genetically modify the large cloned genomic fragment of (a) to create a large targeting vector for use in the embryonic stem cells, the large targeting vector having homology arms greater than 20 kb;

c) introducing the large targeting vector of (b) into isolated mouse embryonic stem cells to replace by homologous recombination, in whole or in part, the endogenous immunoglobulin variable gene locus in the cells; and

d) using a quantitative PCR assay to detect modification of allele (MOA) in the mouse embryonic stem cells of (c) to identify those mouse embryonic stem cells in which the endogenous variable gene locus has been replaced, in whole or in part, with the homologous or orthologous human immunoglobulin variable gene locus.

8. The method of claim 7 further comprising:

e) obtaining a large cloned genomic fragment greater than 20 kb containing a part of the homologous or orthologous human immunoglobulin variable region gene locus that differs from the fragment of (a);

f) using bacterial homologous recombination to genetically modify the cloned genomic fragment of (e) to create a large targeting vector for use in the embryonic stem cells, the large targeting vector having homology arms greater than 20 kb;

g) introducing the large targeting vector of (f) into the mouse embryonic stem cells identified in step (d) to replace by homologous recombination, in whole or in part, the endogenous immunoglobulin variable gene locus; and

h) using a quantitative assay to detect modification of allele (MOA) in the mouse embryonic stem cells of (g) to identify those mouse embryonic stem cells in which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human immunoglobulin variable region gene locus.

9. The method of claim 8 wherein steps (e) through (h) are repeated until the endogenous immunoglobulin variable region gene locus is replaced in whole with an homologous or orthologous human gene locus.

10. The method of claim 7 wherein the immunoglobulin variable gene locus comprises a locus selected from the group consisting of

a) a variable gene locus of the kappa light chain;

b) a variable gene locus of the lambda light chain; and

c) a variable gene locus of the heavy chain.